Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in Understanding the Mechanism(s)

Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000-100 000 platelets/μL), to severe (20 000 to

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Heart Association 2023-12, Vol.12 (24), p.e031855
Hauptverfasser:	Rikken, Sem A O F, van 't Hof, Arnoud W J, Ten Berg, Jurriën M, Kereiakes, Dean J, Coller, Barry S
Format:	Artikel
Sprache:	eng
Schlagworte:	abciximab Abciximab - adverse effects Antibodies, Monoclonal - therapeutic use Contemporary Review Contemporary Reviews eptifibatide Humans Immunoglobulin Fab Fragments - adverse effects Platelet Aggregation Inhibitors - therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex thrombocytopenia Thrombocytopenia - chemically induced tirofiban Tyrosine zalunfiban
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Thrombocytopenia is a rare but serious complication of the intravenous glycoprotein IIb/IIIa (GPIIb/IIIa; integrin αIIbβ3) receptor inhibitors (GPIs), abciximab, eptifibatide, and tirofiban. The thrombocytopenia ranges from mild (50 000-100 000 platelets/μL), to severe (20 000 to
ISSN:	2047-9980 2047-9980
DOI:	10.1161/JAHA.123.031855